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the signiﬁcant impact of perioperative AKI on post-LT outcomes
[2], every attempt to prevent and reverse it in a timely manner
should be made.
Leithead and Ferguson also suggest to cautiously interpret our
ﬁnding concerning the lack of increase in post-LT CKD in the
MELD era, which is discordant with other studies of the national
database [3]. While registry databases provide a large sample
size, they are limited by available data (e.g., measured GFR), lack
of standardization (e.g., assay for serum creatinine), and
completeness (e.g., loss to follow-up). As a single centre study,
we can only report what we observed in our patients – post-
transplant CKD is clearly an important comorbidity; whether
our practice of vigilant monitoring and early intervention was
responsible for the lack of the trend observed in other studies,
remains uncertain.
It may be worth noting that the organ allocation system
should not affect the biological incidence of renal morbidity in
transplant candidates. The primary reason that more patients
are transplanted with reduced renal function is the worsening
organ shortage, which results in more patients developing com-
plications of advanced cirrhosis, such as hepatorenal syndrome
and AKI. The MELD score identiﬁes these patients as their renal
function deteriorates and facilitates access to LT. Should renal
function not be a part of the allocation scheme, further progres-
sion of renal dysfunction would result in increased requirements
for simultaneous kidney transplantation or higher rates of with-
drawal from the waiting list. The net effect of the MELD-based
allocation may be a reduction in these poor waitlist outcomes
at the expense of an increase in incidence of end-stage renal
disease (ESRD), although our data did not show this trend.
Lastly, we agree that directly measured GFR is not a conve-
nient way to monitor our patients long-term. However, we do
believe that clinicians tend to underutilize other measures of
GFR, such as creatinine clearance or serum cystatin-C. Likewise,
an important message in this paper is that serum creatinine or
estimated GFR (often automatically reported by the laboratory)
should not be interpreted in isolation. Changes over time in cre-
atinine or eGFR may help the astute clinician to identify or at
least suspect CKD. Unfortunately, the current CKD classiﬁcation
[4] does not encompass changes in serum creatinine and the
diagnosis of CKD may be missed, due to absent vigilance of the
transplant physician.
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Open acShunt dysfunction: Is it suitable as the primary end point
in transjugular intrahepatic portosystemic shunt trials?To the Editor:
We read with great interest the randomized controlled trial (RCT)
by Perarnau et al. that was published in the Journal of Hepatology
[1]. The ﬁrst RCT on transjugular intrahepatic portosystemic
shunt (TIPS), comparing PTFE-covered stents (CS) with bare
stents (BS) on shunt patency and clinical outcomes, was
published in 2004 [2]. Ten years later, Perarnau et al. concluded
that CS provided a signiﬁcant reduction in shunt dysfunction
evidence to conﬁrm the advantages of CS. However, we still
believe that certain issues merit further discussion.
To begin with, the shunt dysfunction rates in this paper (31.5%
and 44.0% in the CS group vs. 53.8% and 63.6% in the BS group
after 1 and 2 years) were higher than those in the ﬁrst RCT
(12.8% and 34% in the CS group vs. 43.9% and 74% in the BS group
after 1 and 2 years) [1,2]. The authors attribute the outcome var-
iance to differences in patient selection and shunt diameter [1].red to BS. No doubt, this paper has provided additional However, this explanation may be incomplete. For example, the
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shunt dysfunction is symptom recurrence according to the AASLD
guidelines [6]. Furthermore, if shunt dysfunction occurs, what
actions should be taken? Treatments, such as balloon angioplasty
or new stent insertion were provided if shunt dysfunction was
conﬁrmed by the author [1], even though such interventions
may not conform to the clinical reality. In practice, TIPS revision
is only performed when symptoms occur [7]. Hence, the deﬁni-
tion and management of shunt dysfunction still needs further
exploration, and symptom recurrence may be more relevant to
both clinical practice and scientiﬁc studies than shunt
dysfunction.
Therefore, shunt dysfunction may not be the suitable primary
end point of TIPS trials. From our perspective, the best primary
end point should be the problem for which the management
was conducted. The recurrence of symptoms, such as variceal
bleeding and hepatic ascites, may be considered the optimal pri-
mary end point. Thus, we use symptom recurrence to deﬁne
shunt dysfunction in our study [8]. We look forward to further
discussions regarding the optimal primary end point of TIPS
research.
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Fig. 1. Shunt dysfunction caused by stent displacement in a 62-year-old woman. (A) Stent implantation (arrow) during the TIPS procedure. (B) The patient developed
variceal bleeding, and portography conﬁrmed the displacement of the stent (arrow). (C) A new stent was inserted (arrow) in the revision.
Letters to the Editorposition of the stent may also inﬂuence the outcome of TIPS. A
frequency of approximately 20% proximal or distal displacement
was given in the previous American Association for the Study of
Liver Disease (AASLD) guidelines [3]. We also found that stent
displacement may lead to a higher risk of shunt dysfunction in
patients with variceal bleeding [4]. To illustrate the impact of
stent position, we present the following case: A 62-year-old
woman with a history of decompensated hepatitis B-related cir-
rhosis was admitted in our department to undergo TIPS insertion
for the treatment of variceal bleeding. The portosystemic gradi-
ent decreased from 26 mmHg to 10 mmHg after the implantation
of a 8/80 mm Fluency covered stent (Bard, Peripheral Vascular,
Tempe, AZ, USA) (Fig. 1A) on April 17th, 2013. However, the
patient developed variceal bleeding again on April 19th, 2013.
Haemoglobin dropped from 99 g/L to 90 g/L, gastroesophageal
varices and red-signs were seen during upper endoscopy. Direct
portography conﬁrmed that the top of the stent stood out against
the upper wall of the right hepatic vein (Fig. 1B), raising the por-
tosystemic gradient to 16 mmHg as a result. A new stent was
inserted to extend the shunt to the junction of the hepatic vein
and inferior vena cava (Fig. 1C). After TIPS revision, the portosys-
temic pressure gradient decreased to 10 mmHg, and the symp-
toms disappeared. The patient was free of variceal re-bleeding
after one year of follow-up. Thus, the results could be cofounded
by several factors if shunt dysfunction is used as the primary end
point.
Secondly, dysfunction was deﬁned by the authors as an
increase in the portosystemic pressure gradient (PPG) to
P12 mmHg and/or a reduction in the calibre of the stent by
P50% at portography [1]. However, the deﬁnition of shunt dys-
function may differ depending on the underlying liver disease
(i.e. ascites, haemorrhage), which may result in different risks
of shunt dysfunction [5]. We reviewed previous RCTs in TIPS,
and found that RCTs about haemorrhage deﬁned shunt dysfunc-
tion in one or several of the following criteria: (1) Doppler sonog-
raphy: a 20–50% decrease in the stent ﬂow, a portal blood-ﬂow
velocity lower than 10–60 cm/s or over 120 cm/s, or a change
in the direction of the ﬂow in the intrahepatic portal branches;
(2) Angiography: a reduction in the calibre of the stent by
P50% or an occlusion of the shunt; (3) PPG: over 12–15 mmHg.
Meanwhile RCTs on ascites identiﬁed shunt dysfunction through
angiographic ﬁndings and a PPG over 12 mmHg except Doppler
sonography. Thus, no consistent agreement has been reached
among researchers as to the exact judgment criteria of shunt dys-
function. Notably, most physicians rely on Doppler sonography to
monitor shunt dysfunction in practice, but the best indicator of hypertension. Hepatology 2010;51:1–16.
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hypertension in liver cirrhosis. J Hepatol 2011;54:78–88.
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Reply to: ‘‘Shunt dysfunction: Is it suitable as the primary end point
in transjugular intrahepatic portosystemic shunt trials?’’
To the Editor:
We are very honoured by the interest of Han and colleagues for
our study [1]. In their letter two topics were discussed. The ﬁrst
topic was the type of dysfunction in which they underlined and
illustrated the risk of initial stent malposition. The second topic
was in relation with the primary end point of our study. Here,
they suggested the use of clinical recurrence rather than haemo-
dynamics, to qualify shunt dysfunction.
Concerning the ﬁrst point, we noticed that stenoses were
mainly located at the upper end of the TIPS and at the hepatic
vein, with cumulative rates of 63.7% with covered stents and
70.5% with bare stents. A great majority of new stent insertion
and redilation procedures were performed at the ﬁrst six-month
scheduled control. This can effectively address an initial stent
malposition, as described in this interesting case by our Chinese
colleagues. This case report illustrates well how difﬁcult it is, dur-
ing the initial procedure, to adjust the upper side of the TIPS to
the vena cava. It is also difﬁcult to avoid the straightening of
the stent against the hepatic vein wall when withdrawing the
inside catheter. There is no reason why this problem would occur
with a certain type of stent and inﬂuence the results of our com-
parative trial. Furthermore, as our study was multi-centred, this
minimized the inﬂuence of operator dependent bias.
The second point is more disputable. In our study, the primary
end point was to compare short and long term patency of bare
and covered stents independently of their efﬁciency on symp-
toms. As the recurrence of symptoms, which was our secondary
end point, seldom occurred (twelve in all), it was not used as a
discriminator. Variable delay between haemodynamic dysfunc-
tion and clinical recurrence, severity of underlying cirrhosis, or
potential reversibility of some liver diseases explain that shunt
dysfunction and bleeding recurrence are not identical. Thus,
symptom recurrence may not occur despite the presence of shunt
dysfunction when the porto-caval gradient can be reduced after
alcohol withdrawal or virus clearance. Furthermore, we would
like to point out three arguments in favour of haemodynamic
criteria.
First, ascites recurrence does not expose patients to a death
risk, unlike variceal rebleeding. Rebleeding is observed in 20%
of cases with bare stents [2], and in 10% with covered stents.
These events have a proper mortality rate as described by other
teams [1,3–5], which can be estimated at 6% [6]. Waiting for a
symptom to occur is harmful in term of mortality. We have made
the choice to continue to detect shunt dysfunction as early as
possible especially for bleeding indications.
Second, the delay between shunt dysfunction and symptom
recurrence depends on so many parameters that it seems impos-
sible to anticipate. A TIPS which has been completely thrombosed
for a long time, can be technically difﬁcult to recanalize. Some-
times it is impossible and we need to perform a new TIPS besides
the old one. This is why then we prefer to detect and correct
dysfunction early before complete occlusion. The problem lies
in the early detection of shunt dysfunction and we agree with
Cai et al. that Doppler is not a conﬁdent method for screening.
In an ancillary study of STIC-TIPS (submitted paper) we compared
different Doppler parameters without ﬁnding a good sensitive
and speciﬁc marker of dysfunction. Perhaps, as suggested by Rös-
sle, a parameter combining endoscopy and Doppler could provide
this faithful alarm we need to detect TIPS dysfunction [7].
Third, we are not convinced that clinical criteria should
replace haemodynamic criteria in studies dedicated to TIPS in
general. To our knowledge, sensitivity and speciﬁcity of symptom
recurrence to diagnose impaired TIPS patency has not been stud-
ied previously and many confounding variables can interfere
with the diagnosis i.e.: ascites recurrence may be due to either
salt or water restriction modiﬁcation, diuretic variation, cardiac
or renal failure. For multicentre studies non-questionable criteria
are essential and haemodynamic parameters validate this condi-
tion in our opinion. Hepatic venous pressure gradient (HVPG) is
considered as the gold standard for portal hypertension measure-
ment. When Cai et al. checked the patency of their TIPS, they
observed a raise of the portosystemic pressure gradient to
16 mmHg.
Of course, studies exploring the efﬁcacy of TIPS upon different
complications of portal hypertension should have as end point
the clinical recurrence of the indication for TIPS. But we had a
different goal, which was to compare the patency of bare and
covered stents used to perform TIPS.
Finally, it may be important to discuss the need of a system-
atic angiographic TIPS control after 6 months (or earlier) to
correct malposition of the TIPS. Randomized studies about TIPS
treatment or conventional treatment of variceal bleeding or asci-
tes should always have recurrence of indication as a clinical end
point. Randomized controlled trials about methods to treat portal
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